表紙
市場調査レポート

ワクチンの世界市場予測:技術(弱毒化生・トキソイド・共役・合成・樹状細胞・不活化)、種類(予防・治療)、エンドユーザー(小児・成人)、適応症(感染症・癌・アレルギー)別

Vaccine Market: Technology (Live Attenuated, Toxoid, Conjugate, Subunit, Synthetic, Dendritic Cell, Inactivated), Type (Preventive, Therapeutic), End User (Pediatrics, Adults), Disease Indication (Infectious Disease, Cancer, Allergy) - Forecasts to 2019

発行 MarketsandMarkets 商品コード 278597
出版日 ページ情報 英文 211 Pages
即納可能
価格
本日の銀行送金レート: 1USD=106.12円で換算しております。
Back to Top
ワクチンの世界市場予測:技術(弱毒化生・トキソイド・共役・合成・樹状細胞・不活化)、種類(予防・治療)、エンドユーザー(小児・成人)、適応症(感染症・癌・アレルギー)別 Vaccine Market: Technology (Live Attenuated, Toxoid, Conjugate, Subunit, Synthetic, Dendritic Cell, Inactivated), Type (Preventive, Therapeutic), End User (Pediatrics, Adults), Disease Indication (Infectious Disease, Cancer, Allergy) - Forecasts to 2019
出版日: 2015年01月26日 ページ情報: 英文 211 Pages
概要

ワクチン技術市場は2014年の331億4,060万米ドルから11.8%のCAGRで成長し、2019年までに578億8,540万米ドルに達すると予測されています。同市場の主要な成長促進因子は、病気の流行の増加、世界的な予防接種拡大に向けた政府イニチアチブの拡大、ワクチン開発に対する企業投資の増加、および予防接種に向けた非政府組織のイニシアチブの拡大があります。しかし、遠隔地におけるワクチンへの低いアクセシビリティおよび厳しい規制手続きは市場成長を抑制すると予測されています。インドおよび中国といった新興経済国は、ワクチン技術市場に数多くの機会を提示しています。

当レポートでは、ワクチンの世界市場について調査し、市場の概要、種類・技術・適応症・エンドユーザーおよび地域別の市場分析と予測を提供しており、競合情勢や主要企業のプロファイルをまとめ、お届け致します。

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 重要考察

  • 高成長の可能性を持つワクチン技術市場
  • 世界のワクチン技術市場:タイプ別
  • 世界のワクチン技術市場:地域別
  • ワクチン技術市場:適応症別
  • 世界のワクチン技術市場:エンドユーザー別
  • ライフサイクル分析:地域別

第5章 市場概要

  • イントロダクション
  • 市場区分
  • 市場ダイナミクス

第6章 産業の洞察

  • ポーターのファイブフォース分析
  • バリューチェーン分析
  • サプライチェーン分析
  • 技術動向
  • 投資分析
  • 規制情勢
  • 特許分析
  • 主なパイプライン製品
  • 戦略的ベンチマーキング

第7章 ワクチン市場:技術別

  • サブユニットワクチン
  • 弱毒化生ワクチン
  • 共役ワクチン
  • 不活化ワクチン
  • 組み換えベクターワクチン
  • トキソイドワクチン
  • 合成ワクチン
  • 樹状細胞ワクチン

第8章 ワクチン市場:種類別

  • イントロダクション
  • 予防ワクチン
  • 治療ワクチン

第9章 ワクチン市場:適応症別

  • イントロダクション
  • 感染症
    • 肺炎
    • インフルエンザ
    • DTP
    • 肝炎
    • ロタウィルス
    • 水痘
    • 髄膜炎
    • ポリオ
    • MMR
    • その他
  • アレルギー

第10章 ワクチン市場:エンドユーザー別

  • イントロダクション
  • 北米
  • 欧州
  • アジア
  • その他(ROW)

第12章 競合情勢

  • 概要
  • 市場シェア分析
  • 競合状況・動向

第13章 企業プロファイル

  • Glaxosmithkline, PLC.
    • 事業概要
    • 製品ポートフォリオ
    • 主要戦略
    • 近年の発展動向
    • MNMの見解
  • Merck & Co., Inc.
  • SANOFI
  • Pfizer, Inc.
  • Novartis AG
  • Bavarian Nordic
  • CSL Limited
  • Emergent Biosolutions, Inc.
  • Johnson & Johnson
  • Medimmune, LLC. (A Subsidiary of Astrazeneca)

第14章 付録

図表リスト

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: BT 3113

The vaccines market is expected to reach $57,885.4 million by 2019 from $33,140.6 million in 2014, at a CAGR of 11.8%. The global vaccines market is categorized on the basis of type, technology, disease indication, end user, and geography. The preventive vaccines segment is expected to register the highest growth rate in the vaccines market, by type, during the forecast period. Its favorable growth is attributed to the rising prevalence of diseases and increasing number of government initiatives taken for immunization programs worldwide.

Major factors contributing to growth of the vaccines market include rising prevalence of diseases, increasing company investments in vaccine development, and rising initiatives by non-government organizations for vaccinations. Furthermore, government support in the form of funding is another major factor providing impetus for growth of this market. For instance, in November 2014, the U.K. government granted $2 billion (£1.32 billion) to GAVI for the improvement of immunization programs in poor countries. The emerging markets of the Asian region have opened an array of opportunities for the vaccines market. However, low accessibility to vaccines in remote areas and stringent regulatory procedures are expected to restrain the growth of this market.

Apart from the comprehensive geographical and product analysis and market sizing, the report also provides a competitive landscape that covers the growth strategies adopted by the industry players over the last three years. In addition, the company profiles comprise the basic views on the key players in the vaccines market and the product portfolios, developments, and strategies adopted by the market players to maintain and increase their market shares in the near future. The above mentioned market research data, current market size, and forecast of the future trends will help the key players and new entrants to make the necessary decisions regarding product offerings, geographical focus, change in strategic approach, R&D investments for innovations in products and technologies, and levels of output in order to remain successful.

Reasons to Buy the Report:

The report will enrich both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn will help the firms garner a greater market share. Firms purchasing the report can use any one or a combination of the below mentioned five strategies (market penetration, product development/innovation, market development, market diversification, and competitive assessment) for strengthening their market shares.

The report provides insights on the following pointers:

  • Market Penetration: Comprehensive information on product portfolios of the top players in the vaccines market. The report analyzes the vaccines market by type, technology, disease indication, end users, and geography
  • Product Development/Innovation: Detailed insights on the upcoming technologies, R&D activities, and new product launches in the vaccines market
  • Competitive Assessment: In-depth assessment of the market strategies, geographical and business segments, and product portfolios of the leading players in the vaccines market
  • Market Development: Comprehensive information about the lucrative emerging markets. The report analyzes the market for various vaccines across geographies
  • Market Diversification: Exhaustive information about new products and services, untapped geographies, recent developments, and investments in the vaccines market

Table of Contents

1. Introduction

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Scope
    • 1.3.1. Markets Covered
    • 1.3.2. Years Considered for the Study
  • 1.4. Currency
  • 1.5. Limitations
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Market Size Estimation
  • 2.2. Market Breakdown and Data Triangulation
  • 2.3. Market Share Estimation
  • 2.4. Key Data From Secondary Sources
  • 2.5. Key Data From Primary Sources
  • 2.6. Key Industry Insights
  • 2.7. Assumptions

3. Executive Summary

4. Premium Insights

  • 4.1. Vaccine Technology Market to Have High Growth Potential
  • 4.2. Global Vaccine Technology Market, By Type
  • 4.3. Global Vaccine Technology Market, By Region
  • 4.4. Vaccine Technology Market, By Disease Indication
  • 4.5. Global Vaccine Technology Market, By End Users
  • 4.6. Lifecycle Analysis, By Region

5. Market Overview

  • 5.1. Introduction
  • 5.2. Market Segmentation
    • 5.2.1. By Type
    • 5.2.2. By Disease Indication
    • 5.2.3. By End User
    • 5.2.4. By Region
  • 5.3. Market Dynamics
    • 5.3.1. Drivers
      • 5.3.1.1. High Prevalence of Diseases
      • 5.3.1.2. Rising Government and Non-Government Funding for Vaccine Development
      • 5.3.1.3. Increasing Investments By Companies
      • 5.3.1.4. Technological Advancements
    • 5.3.2. Restraints
      • 5.3.2.1. Huge Capital Investments
      • 5.3.2.2. Stringent Regulatory Procedures
    • 5.3.3. Opportunities
      • 5.3.3.1. High Growth Prospects in Emerging Markets
      • 5.3.3.2. Therapeutic Vaccines
      • 5.3.3.3. Adjuvant Vaccines
    • 5.3.4. Challenges
      • 5.3.4.1. Inadequate Access to Vaccines
      • 5.3.4.2. Vaccine Pricing
    • 5.3.5. Burning Issues
      • 5.3.5.1. Failure of Vaccines

6. Industry Insights

  • 6.1. Porter's Five Forces Analysis
    • 6.1.1. Threat From New Entrants
    • 6.1.2. Bargaining Power of Suppliers
    • 6.1.3. Bargaining Power of Buyers
    • 6.1.4. Intensity of Competitive Rivalry
    • 6.1.5. Threat of Substitutes
  • 6.2. Value Chain Analysis
  • 6.3. Supply Chain Analysis
  • 6.4. Technology Trends
    • 6.4.1. Drivers
      • 6.4.1.1. Increasing Use of Adjuvants in Vaccine-Preventable Diseases
      • 6.4.1.2. Rising Government Investments
    • 6.4.2. Restrains
      • 6.4.2.1. High Cost of Research
      • 6.4.2.2. Regulatory Hurdles
    • 6.4.3. Opportunities
      • 6.4.3.1. Combined Adjuvants
      • 6.4.3.2. Vaccines for Young Children
      • 6.4.3.3. Pandemic Diseases
    • 6.4.4. Challenges
      • 6.4.4.1. Identification of Adjuvants
      • 6.4.4.2. Technological Limitations
    • 6.4.5. Trends
      • 6.4.5.1. Collaborations
      • 6.4.5.2. New Adjuvant Technologies
  • 6.5. Investment Analysis
  • 6.6. Regulatory Landscape
    • 6.6.1. North America
    • 6.6.2. Europe
    • 6.6.3. Asia
    • 6.6.4. ROW
  • 6.7. Patent Analysis
  • 6.8. Key Pipeline Products
  • 6.9. Strategic Benchmarking

7. Vaccines Market, By Technology

  • 7.1. Subunit Vaccines
  • 7.2. Live Attenuated Vaccines
  • 7.3. Conjugate Vaccines
  • 7.4. Inactivated Vaccines
  • 7.5. Recombinant Vector Vaccines
  • 7.6. Toxoid Vaccines
  • 7.7. Synthetic Vaccines
  • 7.8. Dendritic Cell Vaccines

8. Vaccines Market, By Type

  • 8.1. Introduction
  • 8.2. Preventive Vaccines
  • 8.3. Therapeutic Vaccines

9. Vaccines Market, By Disease Indication

  • 9.1. Introduction
  • 9.2. Infectious Diseases
    • 9.2.1. Pneumonia
    • 9.2.2. Influenza
    • 9.2.3. DTP
    • 9.2.4. Hepatitis
    • 9.2.5. Rotavirus
    • 9.2.6. Varicella
    • 9.2.7. Meningococcal
    • 9.2.8. Polio
    • 9.2.9. MMR
    • 9.2.10. Others
  • 9.3. Cancer
    • 9.3.1. Cervical Cancer
    • 9.3.2. Others
  • 9.4. Allergies

10. Vaccines Market, By End User

  • 10.1. Introduction
  • 10.2. Pediatrics
  • 10.3. Adults

11. Global Vaccine Technology Market, By Region

  • 11.1. Introduction
  • 11.2. North America
    • 11.2.1. U.S.
    • 11.2.2. Canada
  • 11.3. Europe
    • 11.3.1. Germany
    • 11.3.2. France
    • 11.3.3. U.K.
    • 11.3.4. Italy
    • 11.3.5. Spain
    • 11.3.6. Rest of Europe (ROE)
  • 11.4. Asia
    • 11.4.1. Japan
    • 11.4.2. China
    • 11.4.3. India
    • 11.4.4. Rest of Asia (ROA)
  • 11.5. Rest of the World (ROW)

12. Competitive Landscape

  • 12.1. Overview
  • 12.2. Market Share Analysis
  • 12.3. Competitive Situation and Trends
    • 12.3.1. Agreements, Collaborations & Partnerships
    • 12.3.2. Regulatory Approvals
    • 12.3.3. Acquisitions
    • 12.3.4. Other Developments

13. Company Profiles

  • 13.1. Glaxosmithkline, PLC.
    • 13.1.1. Business Overview
    • 13.1.2. Product Portfolio
    • 13.1.3. Key Strategies
    • 13.1.4. Recent Developments
    • 13.1.5. MNM View
  • 13.2. Merck & Co., Inc.
    • 13.2.1. Business Overview
    • 13.2.2. Product Portfolio
    • 13.2.3. Key Strategy
    • 13.2.4. Recent Developments
    • 13.2.5. MNM View
  • 13.3. SANOFI
    • 13.3.1. Business Overview
    • 13.3.2. Product Portfolio
    • 13.3.3. Key Strategy
    • 13.3.4. Recent Developments
    • 13.3.5. MNM View
  • 13.4. Pfizer, Inc.
    • 13.4.1. Business Overview
    • 13.4.2. Product Portfolio
    • 13.4.3. Key Strategy
    • 13.4.4. Recent Developments
    • 13.4.5. MNM View
  • 13.5. Novartis AG
    • 13.5.1. Business Overview
    • 13.5.2. Product Portfolio
    • 13.5.3. Key Strategy
    • 13.5.4. Recent Developments
    • 13.5.5. MNM View
  • 13.6. Bavarian Nordic
    • 13.6.1. Business Overview
    • 13.6.2. Product Portfolio
    • 13.6.3. Key Strategy
    • 13.6.4. Recent Developments
  • 13.7. CSL Limited
    • 13.7.1. Business Overview
    • 13.7.2. Product Portfolio
    • 13.7.3. Key Strategy
    • 13.7.4. Recent Developments
  • 13.8. Emergent Biosolutions, Inc.
    • 13.8.1. Business Overview
    • 13.8.2. Product Portfolio
    • 13.8.3. Key Strategy
    • 13.8.4. Recent Developments
  • 13.9. Johnson & Johnson
    • 13.9.1. Business Overview
    • 13.9.2. Product Portfolio
    • 13.9.3. Key Strategy
    • 13.9.4. Recent Developments
  • 13.10. Medimmune, LLC. (A Subsidiary of Astrazeneca)
    • 13.10.1. Business Overview
    • 13.10.2. Product Portfolio
    • 13.10.3. Key Strategy
    • 13.10.4. Recent Developments

14. Appendix

  • 14.1. Insights From Industry Experts
  • 14.2. Discussion Guide
  • 14.3. Available Customizations
  • 14.4. Related Reports
  • 14.5. Introducing RT: Real-Time Market Intelligence

List of Tables

  • Table 1: Increasing Prevalence of Diseases to Boost the Market Growth of Vaccines
  • Table 2: Huge Capital Investment to Limit the Market Growth of Vaccines
  • Table 3: Increasing Prevalence of Diseases to Boost the Market Growth of Vaccines
  • Table 4: Increasing Prevalence of Diseases to Boost the Market Growth of Vaccines
  • Table 1: National Institutes of Health (NIH) Funding for Vaccine Development, 2011-2013 ($Million)
  • Table 2: Regulatory Authorities in Europe
  • Table 3: Regulatory Authorities in Asia
  • Table 4: Key Pipeline Vaccines
  • Table 5: Vaccine Market Size, By Technology, 2012-2019 ($Million)
  • Table 6 : ubunit Vaccine Market Size, By Region, 2012-2019 ($Million)
  • Table 7 : orth America: Subunit Vaccine Market Size, By Country, 2012-2019 ($Million)
  • Table 8 : urope: Subunit Vaccines Market Size, By Country, 2012-2019 ($Million)
  • Table 9 : sia: Subunit Vaccines Market Size, By Country, 2012-2019 ($Million)
  • Table 10: Live Attenuated Vaccines Market Size, By Region, 2012-2019 ($Million)
  • Table 11: North America: Live Attenuated Vaccines Market Size, By Country, 2012-2019 ($Million)
  • Table 12: Europe: Live Attenuated Vaccines Market Size, By Country, 2012-2019 ($Million)
  • Table 13: Asia: Live Attenuated Vaccines Market Size, By Country, 2012-2019 ($Million)
  • Table 14: Conjugate Vaccines Market Size, By Region, 2012-2019 ($Million)
  • Table 15: North America: Conjugate Vaccines Market Size, By Country, 2012-2019 ($Million)
  • Table 16: Europe: Conjugate Vaccines Market Size, By Country, 2012-2019 ($Million)
  • Table 17: Asia: Conjugate Vaccines Market Size, By Country, 2012-2019 ($Million)
  • Table 18: Inactivated Vaccines Market Size, By Region, 2012-2019 ($Million)
  • Table 19: North America: Inactivated Vaccines Market Size, By Country, 2012-2019 ($Million)
  • Table 20: Europe: Inactivated Vaccines Market Size, By Country, 2012-2019 ($Million)
  • Table 21: Asia: Inactivated Vaccines Market Size, By Country, 2012-2019 ($Million)
  • Table 22: Recombinant Vector Vaccines Market Size, By Region, 2012-2019 ($Million)
  • Table 23: North America: Recombinant Vector Vaccines Market Size, By Country, 2012-2019 ($Million)
  • Table 24: Europe: Recombinant Vector Vaccines Market Size, By Country, 2012-2019 ($Million)
  • Table 25: Asia: Recombinant Vector Vaccines Market Size, By Country, 2012-2019 ($Million)
  • Table 26: Toxoid Vaccines Market Size, By Region, 2012-2019 ($Million)
  • Table 27: North America: Toxoid Vaccines Market Size, By Country, 2012-2019 ($Million)
  • Table 28: Europe: Toxoid Vaccines Market Size, By Country, 2012-2019 ($Million)
  • Table 29: Asia: Toxoid Vaccines Market Size, By Country, 2012-2019 ($Million)
  • Table 30: Synthetic Vaccines Market Size, By Region, 2012-2019 ($Million)
  • Table 31: North America: Synthetic Vaccines Market Size, By Country, 2012-2019 ($Million)
  • Table 32: Europe: Synthetic Vaccines Market Size, By Country, 2012-2019 ($Million)
  • Table 33: Asia: Synthetic Vaccines Market Size, By Country, 2012-2019 ($Million)
  • Table 34: Dendritic Cell Vaccines Market Size, By Region, 2012-2019 ($Million)
  • Table 35: North America: Dendritic Vaccines Market Size, By Country, 2012-2019 ($Million)
  • Table 36: Europe: Dendritic Cell Vaccines Market Size, By Country, 2012-2019 ($Million)
  • Table 37: Asia: Dendritic Cell Vaccines Market Size, By Country, 2012-2019 ($Million)
  • Table 38: Vaccines Market Size, By Type, 2012-2019 ($Million)
  • Table 39: Preventive Vaccines Market Size, By Region, 2012-2019 ($Million)
  • Table 40: North America: Preventive Vaccines Market Size, By Country, 2012-2019 ($Million)
  • Table 41: Europe: Preventive Vaccines Market Size, By Country, 2012-2019 ($Million)
  • Table 42: Asia: Preventive Vaccines Market Size, By Country, 2012-2019 ($Million)
  • Table 43: Therapeutic Vaccines Market Size, By Region, 2012-2019 ($Million)
  • Table 44: North America: Therapeutic Vaccines Market Size, By Country, 2012-2019 ($Million)
  • Table 45: Europe: Therapeutic Vaccine Market Size, By Country, 2012-2019 ($Million)
  • Table 46: Asia: Therapeutic Vaccines Market Size, By Country, 2012-2019 ($Million)
  • Table 47: Vaccines Market Size, By Disease Indication, 2012-2019 ($Million)
  • Table 48: Vaccines Market Size for Infectious Diseases, By Region, 2012-2019 ($Million)
  • Table 49: North America: Vaccines Market Size for Infectious Diseases, By Country, 2012-2019 ($Million)
  • Table 50: Europe: Vaccine Technology Market Size for Infectious Diseases, By Country, 2012-2019 ($Million)
  • Table 51: Asia: Vaccine Technology Market Size for Infectious Diseases, By Country, 2012-2019 ($Million)
  • Table 52: Infectious Diseases Vaccine Technology Market Size, By Type, 2012-2019 ($Million)
  • Table 53: Vaccine Technology Market Size for Cancer, By Region, 2012-2019 ($Million)
  • Table 54: North America: Vaccine Technology Market Size for Cancer, By Country, 2012-2019 ($Million)
  • Table 55: Europe: Vaccine Technology Market Size for Cancer, By Country, 2012-2019 ($Million)
  • Table 56: Asia: Vaccine Technology Market Size for Cancer, By Country, 2012-2019 ($Million)
  • Table 57: Cancer Vaccine Technology Market Size, By Type, 2012-2019 ($Million)
  • Table 58: Vaccine Technology Market Size for Allergies, By Region, 2012-2019 ($Million)
  • Table 59: North America: Vaccine Technology Market Size for Allergies, By Country, 2012-2019 ($Million)
  • Table 60: Europe: Vaccine Technology Market Size for Allergies, By Country, 2012-2019 ($Million)
  • Table 61: Asia: Vaccine Technology Market Size for Allergies, By Country, 2012-2019 ($Million)
  • Table 62: Vaccine Technology Market Size, By End User, 2012-2019 ($Million)
  • Table 63: Vaccine Technology Market Size for Pediatrics, By Region, 2012-2019 ($Million)
  • Table 64: North America: Vaccine Technology Market Size for Pediatrics, By Country, 2012-2019 ($Million)
  • Table 65: Europe: Vaccine Technology Market Size for Pediatrics, By Country, 2012-2019 ($Million)
  • Table 66: Asia: Vaccine Technology Market Size for Pediatrics, By Country, 2012-2019 ($Million)
  • Table 67: Vaccine Technology Market Size for Adults, By Region, 2012-2019 ($Million)
  • Table 68: North America: Vaccine Technology Market Size for Adults, By Country, 2012-2019 ($Million)
  • Table 69: Europe: Vaccine Technology Market Size for Adults, By Country, 2012-2019 ($Million)
  • Table 70: Asia: Vaccine Technology Market Size for Adults, By Country, 2012-2019 ($Million)
  • Table 71: Vaccine Technology Market Size, By Region, 2012-2019 ($Million)
  • Table 72: North America: Vaccine Technology Market Size, By Country, 2012-2019 ($Million)
  • Table 73: Europe: Vaccine Technology Market Size, By Country, 2012-2019 ($Million)
  • Table 74: Asia: Vaccine Technology Market Size, By Country, 2012-2019 ($Million)
  • Table 75: North America: Vaccine Technology Market Size, By Technology, 2012-2019 ($Million)
  • Table 76: North America: Market Size, By Type, 2012-2019 ($Million)
  • Table 77: North America: Size, Market By Disease Indication, 2012-2019 ($Million)
  • Table 78: North America: Market Size, By End Users, 2012-2019 ($Million)
  • Table 79: U.S.: Vaccine Market Size, By Technology, 2012-2019 ($Million)
  • Table 80: U.S.: Vaccine Technology Market Size, By Type, 2012-2019 ($Million)
  • Table 81: U.S.: Vaccine Technology Market Size, By Disease Indication, 2012-2019 ($Million)
  • Table 82: U.S.: Vaccine Technology Market Size, By End Users, 2012-2019 ($Million)
  • Table 83: Canada: Vaccine Technology Market Size, By Technology, 2012-2019 ($Million)
  • Table 84: Canada: Vaccine Technology Market Size, By Type, 2012-2019 ($Million)
  • Table 85: Canada: Vaccine Technology Market Size, By Disease Indication, 2012-2019 ($Million)
  • Table 86: Canada: Vaccine Technology Market Size, By End Users, 2012-2019 ($Million)
  • Table 87: Europe: Vaccine Technology Market Size, By Technology, 2012-2019 ($Million)
  • Table 88: Europe: Market Size, By Type, 2012-2019 ($Million)
  • Table 89: Europe: Market , By Disease Indication, 2012-2019 ($Million)
  • Table 90: Europe: Market Size, By End Users, 2012-2019 ($Million)
  • Table 91: Germany: Vaccines Technology Market Size, By Technology, 2012-2019 ($Million)
  • Table 92: Germany: Vaccine Technology Market Size, By Type, 2012-2019 ($Million)
  • Table 93: Germany: Vaccine Technology Market Size, By Disease Indication, 2012-2019 ($Million)
  • Table 94: Germany: Vaccine Technology Market Size, By End Users, 2012-2019 ($Million)
  • Table 95: France: Vaccine Technology Market Size, By Technology, 2012-2019 ($Million)
  • Table 96 : rance: Market Size, By Type, 2012-2019 ($Million)
  • Table 97 : rance: Market Size, By Disease Indication, 2012-2019 ($Million)
  • Table 98 : rance: Market Size, By End Users, 2012-2019 ($Million)
  • Table 99 : .K. : Vaccine Technology Market Size, By Technology, 2012-2019 ($Million)
  • Table 100: U.K.: Vaccine Technology Market Size, By Type, 2012-2019 ($Million)
  • Table 101: U.K.: Vaccine Technology Market Size, By Disease Indication, 2012-2019 ($Million)
  • Table 102: U.K.: Vaccine Technology Market Size, By End Users, 2012-2019 ($Million)
  • Table 103: Italy: Vaccine Technology Market Size, By Technology, 2012-2019 ($Million)
  • Table 104: Italy: Vaccine Technology Market Size, By Type, 2012-2019 ($Million)
  • Table 105: Italy: Vaccine Technology Market Size, By Disease Indication, 2012-2019 ($Million)
  • Table 106: Italy: Vaccine Technology Market Size, By End Users, 2012-2019 ($Million)
  • Table 107: Spain: Vaccine Technology Market Size, By Technology, 2012-2019 ($Million)
  • Table 108: Spain: Vaccines Market Size, By Type, 2012-2019 ($Million)
  • Table 109: Spain: Vaccine Technology Market Size, By Disease Indication, 2012-2019 ($Million)
  • Table 110: Spain: Market Size, By End Users, 2012-2019 ($Million)
  • Table 111: ROE: Market Size, By Technology, 2012-2019 ($Million)
  • Table 112: ROE: Vaccine Technology Market Size, By Type, 2012-2019 ($Million)
  • Table 113: ROE: Market Size, By Disease Indication, 2012-2019 ($Million)
  • Table 114: ROE: Market Size, By End Users, 2012-2019 ($Million)
  • Table 115: Asia: Vaccines Technology Market Size, By Technology, 2012-2019 ($Million)
  • Table 116: Asia: Market Size, By Type, 2012-2019 ($Million)
  • Table 117: Asia: Market Size, By Disease Indication, 2012-2019 ($Million)
  • Table 118: Asia: Vaccine Technology Market Size, By End Users, 2012-2019 ($Million)
  • Table 119: Japan: Vaccine Technology Market Size, By Technology, 2012-2019 ($Million)
  • Table 120: Japan: Vaccine Technology Market Size, By Type, 2012-2019 ($Million)
  • Table 121: Japan: Vaccine Technology Market Size, By Disease Indication, 2012-2019 ($Million)
  • Table 122: Japan: Vaccine Technology Market Size, By End Users, 2012-2019 ($Million)
  • Table 123: China: Vaccine Technology Market Size, By Technology, 2012-2019 ($Million)
  • Table 124: China: Vaccine Technology Market Size, By Type, 2012-2019 ($Million)
  • Table 125: China: Market Size, By Disease Indication, 2012-2019 ($Million)
  • Table 126: China: Vaccine Technology Market Size, By End Users, 2012-2019 ($Million)
  • Table 127: India: Vaccine Technology Market Size, By Technology, 2012-2019 ($Million)
  • Table 128: India: Vaccine Technology Market Size, By Type, 2012-2019 ($Million)
  • Table 129: India: Vaccine Technology Market Size, By Disease Indication, 2012-2019 ($Million)
  • Table 130: India: Vaccine Technology Market Size, By End Users, 2012-2019 ($Million)
  • Table 131: ROA: Vaccine Technology Market Size, By Technology, 2012-2019 ($Million)
  • Table 132: ROA: Vaccine Technology Market Size, By Type, 2012-2019 ($Million)
  • Table 133: ROA: Market Size, By Disease Indication, 2012-2019 ($Million)
  • Table 134: ROA: Market Size, By End Users, 2012-2019 ($Million)
  • Table 135: ROW: Market Size, By Technology, 2012-2019 ($Million)
  • Table 136: ROW: Vaccine Technology Market Size, By Type, 2012-2019 ($Million)
  • Table 137: ROW: Market Size, By Disease Indication, 2012-2019 ($Million)
  • Table 138: ROW: Vaccine Technology Market Size, By End Users, 2012-2019 ($Million)
  • Table 139: Recent Agreements and Collaborations
  • Table 140: Recent Regulatory Approvals
  • Table 141: Recent Acquisitions
  • Table 142: Recent Other Developments
  • Table 143: Exchange Rates (Utilized for Conversion of GBP to USD)
  • Table 144: Exchange Rates (Utilized for Conversion of EURO to USD)
  • Table 145: Exchange Rates (Utilized for the Conversion of DKK to USD)

List of Figures

  • Figure 1: Vaccines Market, By Technology
  • Figure 2: Research Methodology
  • Figure 3: Top-Down Approach
  • Figure 4: Bottom-Up Approach
  • Figure 5: Breakdown of Primary Interviews: By Company Type, Designation, and Region
  • Figure 6: Data Triangulation Methodology
  • Figure 7: Vaccine Technology Market Snapshot (2014 vs. 2019): Sub-Unit Vaccines to Grow at Highest CAGR
  • Figure 8: Preventive Vaccines to Dominate the Vaccines Market
  • Figure 9: Pediatric Segment Will Be the Largest End-User Segment in the Vaccines Market
  • Figure 10: North America to Hold Largest Share in the Global Vaccines Market
  • Figure 11: Market Growth Will Be Driven By Prevalence of Diseases
  • Figure 12: Preventive Vaccines Segment Held the Largest Share in Vaccines Market, By Type
  • Figure 13: U.S. Commands One-Third of the Market
  • Figure 14: Infectious Diseases Segment Has A Promising Future in Emerging Economies
  • Figure 15: Pediatrics Segment Will Continue to Lead the Vaccines End-Users Market During the Forecast Period
  • Figure 16: Asia to Witness High Growth Rate in the Vaccines Market During Forecast Period
  • Figure 17: Vaccines Market Segmentation: By Type
  • Figure 18: Vaccines Market Segmentation: By Disease Indication
  • Figure 19: Vaccines Market Segmentation: By End User
  • Figure 20: Vaccines Market Segmentation: By Region
  • Figure 21: Increasing Government Support for Pandemic Threats Likely to Fuel Growth of Vaccines Market
  • Figure 22: Porter's Five Forces Analysis
  • Figure 23: Value Chain Analysis: Major Value is Added During the Development and Manufacturing Phases
  • Figure 24: Supply Chain Analysis
  • Figure 25: Cold Chain Management
  • Figure 26: FDA-Approved Vaccine Adjuvants
  • Figure 27: Licensed Vaccines Containing Adjuvants
  • Figure 28: Examples of Vaccine Adjuvants in Clinical Trials
  • Figure 29: Investors Play an Important Role in the Vaccines Market
  • Figure 30: Vaccine Research Funding, By Type of Investor
  • Figure 31: U.S. Government Agencies Held Largest Share of the HIV R&D Funding in 2013
  • Figure 32: Regulatory Approval Process for Vaccines
  • Figure 33: North America Accounted for the Largest Number of Patent Filings in 2012
  • Figure 34: The U.S. Accounted for Largest Number of Patent Filings Across the Globe (2012)
  • Figure 35: Strategic Benchmarking: Glaxosmithkline, PLC. Largely Adopted Inorganic Growth Strategies for Enhancing Product Offerings
  • Figure 36: Subunit Vaccines Segment to Grow at Highest CAGR in Forecast Period
  • Figure 37: North America to Dominate the Inactivated Vaccines Market From 2014 to 2019
  • Figure 38: Toxoid Vaccines Market in Asia Will Grow at Highest CAGR From 2014 to 2019
  • Figure 39: Reference Figure
  • Figure 40: Preventive Vaccines to Dominate the Global Vaccines Market From 2014 to 2019
  • Figure 41: Asia to Grow at the Highest CAGR From 2014 to 2019
  • Figure 42: Infectious Diseases Segment to Dominate the Vaccines Market From 2014 to 2019
  • Figure 43: The Pediatrics End-User Segment Will Drive the Vaccines Market During the Forecast Period
  • Figure 44: Geographic Snapshot (2014): Emerging Markets Hold Growth Opportunities
  • Figure 45: Geographic Benchmarking for Vaccine Technology Market
  • Figure 46: Market Growth Will Be Driven By Increasing R&D Activities for Development of Vaccines
  • Figure 47: Infectious Diseases Segment Will Continue to Drive the Vaccines Market
  • Figure 48: Germany Will Continue to Dominate the Vaccines Market in Europe
  • Figure 49: German Vaccines Market to Grow at the Highest CAGR in Europe
  • Figure 50: Asia Will Grow at the Highest CAGR in the Vaccines Market
  • Figure 51: Indian Vaccines Market Will Have High Growth Potential
  • Figure 52: Preventive Vaccines Will Lead the Vaccines Market of ROW in 2019
  • Figure 53: Major Players Signed Agreements to Enhance Their Market Positions in the Vaccines Market
  • Figure 54: Global Vaccines Market Share, By Key Player, 2013
  • Figure 55: Battle for Market Share: Agreements Was the Key Strategy Adopted By Market Players
  • Figure 56: Glaxosmithkline, PLC.: Company Snapshot
  • Figure 57: Merck & Co., Inc.: Company Snapshot
  • Figure 58: SANOFI: Company Snapshot
  • Figure 59: Pfizer Inc.: Company Snapshot
  • Figure 60: Novartis AG: Company Snapshot
  • Figure 61: Bavarian Nordic: Company Snapshot
  • Figure 62: CSL Limited: Company Snapshot
  • Figure 63: Emergent Biosolutions: Company Snapshot
  • Figure 64: Johnson & Johnson: Company Snapshot
  • Figure 65: Astrazeneca : Company Snapshot
Back to Top